River Road Asset Management LLC Has $84.78 Million Stock Position in Becton, Dickinson and Company $BDX

River Road Asset Management LLC grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 436,863 shares of the medical instruments supplier’s stock after buying an additional 45,911 shares during the quarter. River Road Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $84,782,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Crux Wealth Advisors boosted its holdings in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after acquiring an additional 49 shares in the last quarter. Larson Financial Group LLC grew its position in Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after acquiring an additional 53 shares during the last quarter. Camelot Portfolios LLC increased its holdings in Becton, Dickinson and Company by 1.5% in the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after purchasing an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC increased its holdings in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock worth $309,000 after purchasing an additional 55 shares in the last quarter. Finally, Atlantic Union Bankshares Corp raised its holdings in Becton, Dickinson and Company by 0.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after buying an additional 57 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the sale, the executive vice president owned 14,272 shares of the company’s stock, valued at approximately $2,161,922.56. The trade was a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,013 shares of company stock worth $593,434 in the last ninety days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $143.99 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a 50 day simple moving average of $149.15 and a two-hundred day simple moving average of $172.51. The company has a market capitalization of $39.67 billion, a PE ratio of 36.45, a P/E/G ratio of 10.02 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the previous year, the company earned $3.35 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Wall Street Analyst Weigh In

BDX has been the subject of several recent research reports. Stifel Nicolaus decreased their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Evercore boosted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Bank of America decreased their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. The Goldman Sachs Group lowered their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. Finally, Piper Sandler cut their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $181.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.